Level of Plasmacytoid Dendritic Cells is Increased in Non-small Cell Lung Carcinoma

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2013 Oct 19

PMID 24136746

Citations 14

Authors

Weiwei Shi

Xiaoyan Li

Jerry L Porter

David H Ostrodi

Bo Yang

Juan Li

Yishang Wang

Juan Zhang

Li Bai

Shunchang Jiao

Affiliations

Soon will be listed here.

Abstract

In non-small cell lung carcinoma (NSCLC), the immune system fails to eradicate established tumors partly due to the induction of immune tolerance within the tumor microenvironment. Plasmacytoid dendritic cells (pDCs) play critical roles in regulating the immune system. In this study, we investigated pDCs in the peripheral blood of NSCLC. CD4 + CD123 + BDCA2+ pDCs were tested from peripheral blood mononuclear cells in 52 NSCLC patients and 52 healthy controls by flow cytometry. Results revealed that proportion of pDCs was significantly increased in cases than in controls (0.52 ± 0.07% versus 0.21 ± 0.02%, p < 0.001), whereas myeloid dendritic cells (mDCs) did not present any obvious difference between patients and healthy donors (0.25 ± 0.04 % versus 0.18 ± 0.02%, p = 0.120). We further studied pDCs in NSCLC patients with different clinical stages. Data showed that cases with higher stages (III/IV) had elevated level of pDCs than those with lower stages (I/II) (0.65 ± 0.09% versus 0.25 ± 0.07%, p = 0.006). In addition, the amount of pDCs was identified to be associated with squamous cell carcinoma, one of the major subtypes of NSCLC. Interestingly, we observed that smoking patients presented significantly elevated pDCs than those non-smokers (0.63 ± 0.09% versus 0.22 ± 0.05%, p = 0.008). These data suggested that pDCs may be closely involved in the pathogenesis of NSCLC and may predict the progression of the disease.

Citing Articles

Characteristics of tumor microenvironment and novel immunotherapeutic strategies for non-small cell lung cancer.

Wang F, Yang M, Luo W, Zhou Q J Natl Cancer Cent. 2024; 2(4):243-262.

PMID: 39036549 PMC: 11256730. DOI: 10.1016/j.jncc.2022.10.002.

Plasmacytoid dendritic cells at the forefront of anti-cancer immunity: rewiring strategies for tumor microenvironment remodeling.

Monti M, Ferrari G, Gazzurelli L, Bugatti M, Facchetti F, Vermi W J Exp Clin Cancer Res. 2024; 43(1):196.

PMID: 39020402 PMC: 11253500. DOI: 10.1186/s13046-024-03121-9.

Dendritic Cells in Shaping Anti-Tumor T Cell Response.

Mazzoccoli L, Liu B Cancers (Basel). 2024; 16(12).

PMID: 38927916 PMC: 11201542. DOI: 10.3390/cancers16122211.

Accumulation of plasmacytoid dendritic cell is associated with a treatment response to DNA-damaging treatment and favorable prognosis in lung adenocarcinoma.

Cha Y, Kim E, Choi Y, Kim C, Park M, Chang Y Front Immunol. 2023; 14:1154881.

PMID: 37435086 PMC: 10330699. DOI: 10.3389/fimmu.2023.1154881.

Plasmacytoid Dendritic Cells as a Novel Cell-Based Cancer Immunotherapy.

Hernandez S, Jakobsen M, Bak R Int J Mol Sci. 2022; 23(19).

PMID: 36232698 PMC: 9570010. DOI: 10.3390/ijms231911397.

References

Liu Y . IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol. 2005; 23:275-306. DOI: 10.1146/annurev.immunol.23.021704.115633. View

Sorrentino R, Morello S, Forte G, Montinaro A, De Vita G, Luciano A . B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma. Am J Respir Crit Care Med. 2011; 183(10):1369-79. DOI: 10.1164/rccm.201010-1738OC. View

Sharma M, Baban B, Chandler P, Hou D, Singh N, Yagita H . Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest. 2007; 117(9):2570-82. PMC: 1940240. DOI: 10.1172/JCI31911. View

Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, Miltenyi S . BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol. 2000; 165(11):6037-46. DOI: 10.4049/jimmunol.165.11.6037. View

Siegal F, Kadowaki N, Shodell M, Shah K, Ho S, Antonenko S . The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999; 284(5421):1835-7. DOI: 10.1126/science.284.5421.1835. View

Jego G, Palucka A, Blanck J, Chalouni C, Pascual V, Banchereau J . Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity. 2003; 19(2):225-34. DOI: 10.1016/s1074-7613(03)00208-5. View

Lonsdorf A, Kuekrek H, Stern B, Boehm B, Lehmann P, Tary-Lehmann M . Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J Immunol. 2003; 171(8):3941-6. DOI: 10.4049/jimmunol.171.8.3941. View

Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A . Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med. 1999; 5(8):919-23. DOI: 10.1038/11360. View

Sorrentino R, Morello S, Luciano A, Crother T, Maiolino P, Bonavita E . Plasmacytoid dendritic cells alter the antitumor activity of CpG-oligodeoxynucleotides in a mouse model of lung carcinoma. J Immunol. 2010; 185(8):4641-50. DOI: 10.4049/jimmunol.1000881. View

10.

Lawrence R, Salgia R . MET molecular mechanisms and therapies in lung cancer. Cell Adh Migr. 2010; 4(1):146-52. PMC: 2852571. DOI: 10.4161/cam.4.1.10973. View

11.

Paquette R, Hsu N, Said J, Mohammed M, Rao N, Shih G . Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo. Leukemia. 2002; 16(8):1484-9. DOI: 10.1038/sj.leu.2402602. View

12.

Li X, Shi W, Yu G, Lin L, Yang B, Li J . Interleukin-4 -590T/C polymorphism influences the susceptibility to nonsmall cell lung cancer. DNA Cell Biol. 2011; 31(5):797-800. DOI: 10.1089/dna.2011.1425. View

13.

Jan de Heer H, Hammad H, Soullie T, Hijdra D, Vos N, Willart M . Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J Exp Med. 2004; 200(1):89-98. PMC: 2213319. DOI: 10.1084/jem.20040035. View

14.

Perrot I, Blanchard D, Freymond N, Isaac S, Guibert B, Pacheco Y . Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol. 2007; 178(5):2763-9. DOI: 10.4049/jimmunol.178.5.2763. View

15.

Kamath A, Sheasby C, Tough D . Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma. J Immunol. 2005; 174(2):767-76. DOI: 10.4049/jimmunol.174.2.767. View

16.

Ochando J, Homma C, Yang Y, Hidalgo A, Garin A, Tacke F . Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol. 2006; 7(6):652-62. DOI: 10.1038/ni1333. View

17.

Palamara F, Meindl S, Holcmann M, Luhrs P, Stingl G, Sibilia M . Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol. 2004; 173(5):3051-61. DOI: 10.4049/jimmunol.173.5.3051. View

18.

Yoneyama H, Matsuno K, Zhang Y, Nishiwaki T, Kitabatake M, Ueha S . Evidence for recruitment of plasmacytoid dendritic cell precursors to inflamed lymph nodes through high endothelial venules. Int Immunol. 2004; 16(7):915-28. DOI: 10.1093/intimm/dxh093. View

19.

Umemoto E, Otani K, Ikeno T, Verjan Garcia N, Hayasaka H, Bai Z . Constitutive plasmacytoid dendritic cell migration to the splenic white pulp is cooperatively regulated by CCR7- and CXCR4-mediated signaling. J Immunol. 2012; 189(1):191-9. DOI: 10.4049/jimmunol.1200802. View

20.

Goubier A, Dubois B, Gheit H, Joubert G, Villard-Truc F, Asselin-Paturel C . Plasmacytoid dendritic cells mediate oral tolerance. Immunity. 2008; 29(3):464-75. PMC: 3545652. DOI: 10.1016/j.immuni.2008.06.017. View